Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$149.27 USD
-0.65 (-0.43%)
Updated May 3, 2024 04:00 PM ET
After-Market: $149.72 +0.45 (0.30%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
JNJ 149.27 -0.65(-0.43%)
Will JNJ be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JNJ
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Other News for JNJ
Johnson & Johnson: A Healthcare Giant That's Looking More Attractive By The Day
5 Relatively Secure And Cheap Dividend Stocks To Invest In - May 2024
Pharma R&D productivity seen improving for the first time in years - Deloitte
5 Expected Dividend Increases In May 2024
J&J releases new Erleada data buoying benefit of prostate cancer treatment